Drugs / FIRUGLIPEL
last change Sep 2017 re-read 2 minutes ago

FIRUGLIPEL

also known as DS-8500a

Small molecule

Developed for
type 2 diabetes mellitus
Investigated by
Daiichi Sankyo · Mediscience Planning, Inc.

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT02790684 May → Jun 2016 Daiichi Sankyo Completed No outcome recorded
Phase 1 NCT02790671 May → Jun 2016 Daiichi Sankyo Completed No outcome recorded
Phase 1 NCT03699774 May → Jul 2015 Daiichi Sankyo Completed No outcome recorded
Phase 23 trials
Phase 2 NCT02685345 Jan → Sep 2016 type 2 diabetes mellitus Daiichi Sankyo Completed No outcome recorded
Phase 2 NCT02647320 Jan 2016 → Jan 2017 type 2 diabetes mellitus Daiichi Sankyo Completed No outcome recorded
Phase 2 NCT02222350 Jul → Nov 2014 type 2 diabetes mellitus Daiichi Sankyo Completed No outcome recorded
Phase not applicable2 trials
NCT02669732 Jan → Aug 2016 type 2 diabetes mellitus Daiichi Sankyo Completed No outcome recorded
NCT02628392 Nov 2015 → Sep 2016 type 2 diabetes mellitus Daiichi Sankyo Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as FIRUGLIPEL ChEMBL registry synonym — accepted as the source's own label CHEMBL5314955
Known as DS-8500a ClinicalTrials.gov intervention name — accepted as the source's own label NCT02790671
7

NCT02669732

NCT02222350

NCT02790684

NCT02685345

NCT02647320

NCT03699774

NCT02628392

Action Activate “G protein-coupled receptor 119 agonist” PMID 29071087 Sep 2017
Modality Small molecule CHEMBL5314955
Route Oral “DS-8500a 10 mg and 75 mg administered orally, once daily, for 28 days” NCT02222350